Intech Investment Management LLC Takes $94,000 Position in Inogen, Inc. (NASDAQ:INGN)

Intech Investment Management LLC bought a new position in Inogen, Inc. (NASDAQ:INGN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,285 shares of the medical technology company’s stock, valued at approximately $94,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in INGN. Royce & Associates LP raised its holdings in shares of Inogen by 499.7% during the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company’s stock worth $2,854,000 after acquiring an additional 259,308 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Inogen by 42.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company’s stock worth $2,282,000 after purchasing an additional 74,197 shares during the last quarter. Monaco Asset Management SAM raised its stake in Inogen by 104.0% during the fourth quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company’s stock valued at $702,000 after purchasing an additional 39,000 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Inogen by 23.5% during the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company’s stock valued at $1,160,000 after purchasing an additional 24,082 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Inogen by 2.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after buying an additional 23,891 shares in the last quarter. 89.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Wednesday, February 26th.

Inogen Stock Down 0.4 %

INGN stock opened at $7.14 on Friday. The firm’s fifty day simple moving average is $9.48 and its two-hundred day simple moving average is $9.58. The stock has a market capitalization of $189.42 million, a price-to-earnings ratio of -3.17 and a beta of 1.15. Inogen, Inc. has a twelve month low of $6.14 and a twelve month high of $13.33.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.